|
|||
|
DRUGS & SUPPLEMENTS
|
Dextrose 5% and Sodium Chloride 0.45%
When are you taking this medicine? |
Dextrose 5% and Sodium Chloride 0.45% uses
- Indications and usage
- Contraindications
- Warnings
- Precautions
- Adverse reactions
- Overdosage
- Dosage and administration
- Instructions for use
- How supplied
INDICATIONS AND USAGE
Intravenous solutions containing Dextrose 5% and Sodium Chloride 0.45% are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.
CONTRAINDICATIONS
None known.
WARNINGS
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
Excessive administration of potassium-free solutions may result in significant hypokalemia.
In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.
The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
PRECAUTIONS
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions to patients receiving corticosteroids or corticotropin.
Do not administer unless solution is clear and container is undamaged. Discard unused portion.
Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose or sodium chloride. It is also not known whether dextrose or sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose or sodium chloride should be given to a pregnant woman only if clearly needed.
Pediatric Use. The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants, the volume of fluid may affect fluid and electrolyte balance.
Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.
In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
Geriatric Use. An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sodium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
ADVERSE REACTIONS
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
OVERDOSAGE
In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .
DOSAGE AND ADMINISTRATION
The dose is dependent upon the age, weight and clinical condition of the patient.
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS .
Drug Interactions
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
INSTRUCTIONS FOR USE
To Open:
Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration.
To Add Medication
- Prepare additive port.
- Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.
- The additive port may be protected by covering with an additive cap.
- Mix container contents thoroughly.
Preparation for Administration
(Use aseptic technique)
- Close flow control clamp of administration set.
- Remove cover from outlet port at bottom of container.
- Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: When using a vented administration set, replace bacterial retentive air filter with piercing pin cover. Insert piercing pin with twisting motion until shoulder of air filter housing rests against the outlet port flange.
- Suspend container from hanger.
- Squeeze and release drip chamber to establish proper fluid level in chamber.
- Attach venipuncture device to set.
- Open clamp to expel air from set and venipuncture device. Close clamp.
- Perform venipuncture.
- Regulate rate of administration with flow control clamp.
WARNING: Do not use flexible container in series connections.
HOW SUPPLIED
Dextrose 5% and Sodium Chloride 0.45% Injection, USP are supplied in single-dose flexible plastic containers in various sizes and concentrations as shown in the accompanying Table.
| | | |||||||||
| NDC No. | Product | Dextrose (hydrous) | Sodium Chloride | Sodium Na+ | Chloride Cl¯ | Caloric Value | Tonicity | Osmolarity mOsmol/L (calc) | pH | Container size (mL) |
| 0409-7924-02 | 5% Dextrose and 0.225% Sodium Chloride Inj., USP | 5 | 0.225 | 38.5 mEq | 38.5 mEq | 170 | Hypertonic | 329 | 4.3 (3.5 to 6.5) | 250 |
| 0409-7924-03 | 5% Dextrose and 0.225% Sodium Chloride Inj., USP | 5 | 0.225 | 38.5 mEq | 38.5 mEq | 170 | Hypertonic | 329 | 4.3 (3.5 to 6.5) | 500 |
| 0409-7924-09 | 5% Dextrose and 0.225% Sodium Chloride Inj., USP | 5 | 0.225 | 38.5 mEq | 38.5 mEq | 170 | Hypertonic | 329 | 4.3 (3.5 to 6.5) | 1000 |
| 0409-7925-02 | 5% Dextrose and 0.3% Sodium Chloride Inj., USP | 5 | 0.3 | 51 mEq | 51 mEq | 170 | Hypertonic | 355 | 4.3 (3.5 to 6.5) | 250 |
| 0409-7925-03 | 5% Dextrose and 0.3% Sodium Chloride Inj., USP | 5 | 0.3 | 51 mEq | 51 mEq | 170 | Hypertonic | 355 | 4.3 (3.5 to 6.5) | 500 |
| 0409-7925-09 | 5% Dextrose and 0.3% Sodium Chloride Inj., USP | 5 | 0.3 | 51 mEq | 51 mEq | 170 | Hypertonic | 355 | 4.3 (3.5 to 6.5) | 1000 |
| 0409-7926-02 | 5% Dextrose and 0.45% Sodium Chloride Inj., USP | 5 | 0.45 | 77 mEq | 77 mEq | 170 | Hypertonic | 406 | 4.3 (3.5 to 6.5) | 250 |
| 0409-7926-03 | 5% Dextrose and 0.45% Sodium Chloride Inj., USP | 5 | 0.45 | 77 mEq | 77 mEq | 170 | Hypertonic | 406 | 4.3 (3.5 to 6.5) | 500 |
| 0409-7926-09 | 5% Dextrose and 0.45% Sodium Chloride Inj., USP | 5 | 0.45 | 77 mEq | 77 mEq | 170 | Hypertonic | 406 | 4.3 (3.5 to 6.5) | 1000 |
| 0409-7941-02 | 5% Dextrose and 0.9% Sodium Chloride Inj., USP | 5 | 0.9 | 154 mEq | 154 mEq | 170 | Hypertonic | 560 | 4.3 (3.5 to 6.5) | 250 |
| 0409-7941-03 | 5% Dextrose and 0.9% Sodium Chloride Inj., USP | 5 | 0.9 | 154 mEq | 154 mEq | 170 | Hypertonic | 560 | 4.3 (3.5 to 6.5) | 500 |
| 0409-7941-09 | 5% Dextrose and 0.9% Sodium Chloride Inj., USP | 5 | 0.9 | 154 mEq | 154 mEq | 170 | Hypertonic | 560 | 4.3 (3.5 to 6.5) | 1000 |
Protect from freezing. Store at 20 to 25°C (68 to 77°F).
Revised: June, 2009
Printed in USA EN-2179
Hospira, Inc., Lake Forest, IL 60045 USA
1000 mL
NDC 0409-7924-09
5% DEXTROSE
and 0.225%
SODIUM CHLORIDE
Injection, USP
EACH 100 mL CONTAINS DEXTROSE,
HYDROUS 5 g; SODIUM CHLORIDE
225 mg IN WATER FOR INJECTION.
ELECTROLYTES PER 1000 mL: SODIUM
38.5 mEq; CHLORIDE 38.5 mEq.
329 mOsmol/LITER (CALC).
pH 4.3 (3.5 to 6.5).
ADDITIVES MAY BE INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF
AVAILABLE. WHEN INTRODUCING
ADDITIVES, USE ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO NOT STORE.
SINGLE-DOSE CONTAINER. FOR I.V. USE.
USUAL
Dosage: SEE INSERT. STERILE,
NONPYROGENIC. USE ONLY IF
SOLUTION IS CLEAR AND CONTAINER IS
UNDAMAGED. MUST NOT BE USED IN
SERIES CONNECTIONS.
Rx ONLY
3
v
CONTAINS DEHP
Hospira
©HOSPIRA 2004
IM-0159 (10/04)
PRINTED IN USA
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Dextrose 5% and Sodium Chloride 0.45% pharmaceutical active ingredients containing related brand and generic drugs:
Dextrose 5% and Sodium Chloride 0.45% available forms, composition, doses:
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.